• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » John Fox

Articles by John Fox

Stem cell treatment shows promise in severe spina bifida

June 20, 2017
By John Fox
A Japanese study has demonstrated a new management approach for fetuses with myelomeningocele (MMC), one of the most severe forms of spina bifida, employing 3-D skin reconstructed using induced pluripotent stem cells (iPSCs) derived from maternal amniotic fluid cells (AFCs).
Read More

Viable new pain relief target identified in Australia

June 14, 2017
By John Fox

Viable new pain relief target identified in Australia

June 14, 2017
By John Fox
Therapeutic targeting of endosomal GTP-binding (G protein)-coupled receptors (GPCRs) is a novel means of drug delivery that may offer more effective and selective treatment for chronic pain and possibly other conditions, a study by Australian researchers at Monash University in Melbourne has concluded.
Read More

Mitochondrial dysfunction leads to motor problems in fly model of Parkinson's

June 14, 2017
By John Fox
A new study by Japanese researchers has shown how the loss of a key mitochondrial protein facilitates progression of Parkinson's disease (PD), identifying a new therapeutic target and hence the potential for the discovery and development of new PD treatments.
Read More

Viable new pain relief target identified in Australia

June 12, 2017
By John Fox
Therapeutic targeting of endosomal GTP-binding (G protein)-coupled receptors (GPCRs) is a novel means of drug delivery that may offer more effective and selective treatment for chronic pain and possibly other conditions, a study by Australian researchers at Monash University in Melbourne has concluded.
Read More

Statins are able to overcome osteosarcoma metastasis and stemness

June 7, 2017
By John Fox
A new Chinese study's findings suggest Adriamycin-based chemotherapy may simulate cancer stem cells (CSCs) through transcription factor signaling activation, but that such signaling is inhibited by statins. Reported in the May 25, 2017, online edition of Stem Cell Reports, the results may be important in designing new osteosarcoma treatment regimens.
Read More

Potential therapeutic target pathway is identified in ALS

June 1, 2017
By John Fox

Statins are able to overcome osteosarcoma metastasis and stemness

June 1, 2017
By John Fox
A new Chinese study’s findings suggest Adriamycin-based chemotherapy may simulate cancer stem cells (CSCs) through transcription factor signaling activation, but that such signaling is inhibited by statins. Reported in the May 25, 2017, online edition of Stem Cell Reports, the results may be important in designing new osteosarcoma treatment regimens.
Read More

Potential new therapeutic target pathway identified in ALS

May 31, 2017
By John Fox
Japanese researchers have screened existing drugs for potential to treat amyotrophic lateral sclerosis (ALS) using neurons developed from induced pluripotent stem (iPS) cells of a patient with an ALS gene mutation, thereby identifying a potential new target pathway for drugs against the currently incurable disease.
Read More

Potential therapeutic target pathway is identified in ALS

May 31, 2017
By John Fox
Japanese researchers have screened existing drugs for potential to treat amyotrophic lateral sclerosis (ALS) using neurons developed from induced pluripotent stem (iPS) cells of a patient with an ALS gene mutation, thereby identifying a potential new target pathway for drugs against the currently incurable disease.
Read More
Previous 1 2 … 34 35 36 37 38 39 40 41 42 … 68 69 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe